Novo Nordisk at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Novo Nordisk brings 8 presentations to ASH 2026 in New Orleans, and exhibits at Booth 913. Novo Nordisk presents sessions on hemophilia management and its sickle cell drug development, and supports a symposium on sickle cell therapies. Research covers patient preferences in hemophilia and etavopivat.
| Organization | ASH 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company; its rare disease unit develops treatments for hemophilia and other rare blood disorders, including sickle cell disease. | Booth Exhibiting at Booth 913 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. Oral Sat Dec 12 12:00pm–1:30pm Poster Sat Dec 12 5:30pm–7:30pm Talk Sun Dec 13 8:00am–9:00am Talk Sun Dec 13 9:30am–11:00am Talk Mon Dec 14 12:15pm–1:15pm Oral Mon Dec 14 2:45pm–4:15pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Find decision makers at Novo Nordisk
Tell us what you sell and we’ll find the people at Novo Nordisk most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction